Trial Profile
A prospective, open-label clinical trial, to evaluate the efficacy of intravitreal Aflibercept for the treatment of treatment resistant diabetic macular oedema
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 May 2020
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Diabetic macular oedema
- Focus Therapeutic Use
- 01 Jun 2017 Status changed from recruiting to completed.
- 19 Dec 2014 New trial record